Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulphonamide-based small molecule VLA-4 antagonists.

Marcin Stasiak1, Christopher Mehlin, Erica Boni

  • 1Molecumetics, 2023 120th Avenue N E., Bellevue, WA 98005, USA.

Bioorganic & Medicinal Chemistry Letters
|October 14, 2003
PubMed
Summary

Researchers discovered a novel sulphonamide by-product with very late antigen-4 (VLA-4) antagonistic activity. This led to the development of potent, small molecule VLA-4 antagonists, with synthesis and in vivo data presented.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia.

Blood neoplasia·2026
Same author

The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells.

The Journal of clinical investigation·2026
Same author

Shape and Morphology of the Sella Turcica in Patients with Trisomy 21-A Systematic Review.

Diagnostics (Basel, Switzerland)·2026
Same author

Molecular ART in the Atherosclerotic Lesion: ADP-Ribosylation.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

Focal Adhesion Kinase Drives Rho/ROCK and mTOR Signaling to Protect and Augment Aortic Dissections.

JACC. Basic to translational science·2025
Same author

Elevated apolipoprotein C3 heightens atherosclerosis risk by mediating arterial accumulation of free cholesterol and local inflammation in diabetes.

Research square·2025

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Drug Discovery

Background:

  • Very late antigen-4 (VLA-4) is a key adhesion molecule involved in inflammatory and autoimmune diseases.
  • Targeting VLA-4 offers a therapeutic strategy for various immune-mediated conditions.
  • The discovery of a sulphonamide by-product with VLA-4 antagonistic activity initiated a new drug development program.

Purpose of the Study:

  • To present the synthesis of novel small molecule VLA-4 antagonists.
  • To detail the structure-activity relationship (SAR) studies conducted.
  • To report the in vivo evaluation of a selected lead compound.

Main Methods:

  • Chemical synthesis of a series of sulphonamide-based compounds.
  • In vitro assays to assess VLA-4 antagonistic activity.

Related Experiment Videos

  • Pharmacokinetic and pharmacodynamic studies in animal models.

    • Main Results:

    • Identification of a potent sulphonamide by-product with VLA-4 antagonistic properties.
    • Establishment of SAR for optimizing VLA-4 antagonist potency and selectivity.
    • Demonstration of in vivo efficacy of a selected small molecule antagonist.

    Conclusions:

    • Small molecule VLA-4 antagonists derived from a sulphonamide scaffold are feasible.
    • The developed compounds show promise for treating VLA-4 mediated diseases.
    • Further investigation into these antagonists is warranted for therapeutic development.